董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rachel Ellingson | 女 | Director | 55 | 25.55万美元 | 未持股 | 2025-08-20 |
| Amy DuRoss | 女 | Lead Independent Director | 51 | 30.80万美元 | 未持股 | 2025-08-20 |
| Joydeep Goswami | 男 | Director | 54 | 27.13万美元 | 未持股 | 2025-08-20 |
| Tim Moore | 男 | Director | 64 | 25.55万美元 | 未持股 | 2025-08-20 |
| Cathy Coste | 女 | Director | 59 | 未披露 | 未持股 | 2025-08-20 |
| Tony Hunt | 男 | Director | 61 | 未披露 | 未持股 | 2025-08-20 |
| Roderick de Greef | 男 | Chief Executive Officer and Chairman of the Board | 64 | 704.62万美元 | 未持股 | 2025-08-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Todd Berard | 男 | Chief Commercial Officer | 56 | 112.75万美元 | 未持股 | 2025-08-20 |
| Karen Foster | 女 | Chief Quality and Operations Officer | 65 | 151.51万美元 | 未持股 | 2025-08-20 |
| Troy Wichterman | 男 | Chief Financial Officer | 41 | 255.40万美元 | 未持股 | 2025-08-20 |
| Sarah Aebersold | 女 | Chief Human Resources Officer | 50 | 未披露 | 未持股 | 2025-08-20 |
| Sean Werner | 男 | Chief Technology Officer | 51 | 未披露 | 未持股 | 2025-08-20 |
| Roderick de Greef | 男 | Chief Executive Officer and Chairman of the Board | 64 | 704.62万美元 | 未持股 | 2025-08-20 |
| Aby J. Mathew | 男 | Chief Scientific Officer and Executive Vice President | 53 | 173.35万美元 | 未持股 | 2025-08-20 |
董事简历
中英对照 | 中文 | 英文- Rachel Ellingson
-
Rachel Ellingson于2018年4月被任命为高级副总裁兼首席战略官，并于2021年1月被任命为执行官。加入Zimmer Biomet之前，她曾担任St. Jude Medical的执行领导团队成员（2012年至2017年），最近担任战略副总裁（2015年至2017年）。在加入St. Jude Medical之前，她曾担任AGA Medical Corporation的业务发展和投资者关系副总裁。在加入AGA Medical之前，Ellingson女士拥有超过15年的投资银行经验，并在美国银行（Bank of America）担任医疗技术投资银行董事总经理。她自2021年4月起担任Biolife Solutions， Inc.的董事会成员，并担任其审计和薪酬委员会成员。
Rachel Ellingson,has served as a director and member of Biolife Solutions, Inc. Compensation Committee and Audit Committee since April 2021. Since March 2025, Ms. Ellingson has served as Chief Strategy and Corporate Development Officer at Solventum (NYSE: SOLV), a diversifie d medical device company. As a member of the executive leadership team at SOLV, Ms. Ellingson is responsible for global oversight of strategy, business development, integration, and divestitures. Prior to her appointment at SOLV, Ms. Ellingson served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a medical device company focused in orthopedics from April 2018 to March 2025. Ms. Ellingson also served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical, Inc., a medical device company focused on cardiovascular and neuromodulation therapies, from 2011 to 2017. Before joining St. Jude Medical, Ms. Ellingson served as Vice President, Business Development and Investor Relations at AGA Medical Corporation, a developer and manufacturer of cardiovascular medical devices. Ms. Ellingson was an investment banker prior to her appointment at AGA Medical, serving as a Managing Director in the Healthcare Investment Banking sector of Bank of America Corporation (NYSE: BAC) and prior to that, was with Cowen & Company (NASDAQ: COWN). Ms. Ellingson holds an MBA in Finance from the University of Connecticut and a Bachelor of Arts degree from the University of Rhode Island. - Rachel Ellingson于2018年4月被任命为高级副总裁兼首席战略官，并于2021年1月被任命为执行官。加入Zimmer Biomet之前，她曾担任St. Jude Medical的执行领导团队成员（2012年至2017年），最近担任战略副总裁（2015年至2017年）。在加入St. Jude Medical之前，她曾担任AGA Medical Corporation的业务发展和投资者关系副总裁。在加入AGA Medical之前，Ellingson女士拥有超过15年的投资银行经验，并在美国银行（Bank of America）担任医疗技术投资银行董事总经理。她自2021年4月起担任Biolife Solutions， Inc.的董事会成员，并担任其审计和薪酬委员会成员。
- Rachel Ellingson,has served as a director and member of Biolife Solutions, Inc. Compensation Committee and Audit Committee since April 2021. Since March 2025, Ms. Ellingson has served as Chief Strategy and Corporate Development Officer at Solventum (NYSE: SOLV), a diversifie d medical device company. As a member of the executive leadership team at SOLV, Ms. Ellingson is responsible for global oversight of strategy, business development, integration, and divestitures. Prior to her appointment at SOLV, Ms. Ellingson served as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a medical device company focused in orthopedics from April 2018 to March 2025. Ms. Ellingson also served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical, Inc., a medical device company focused on cardiovascular and neuromodulation therapies, from 2011 to 2017. Before joining St. Jude Medical, Ms. Ellingson served as Vice President, Business Development and Investor Relations at AGA Medical Corporation, a developer and manufacturer of cardiovascular medical devices. Ms. Ellingson was an investment banker prior to her appointment at AGA Medical, serving as a Managing Director in the Healthcare Investment Banking sector of Bank of America Corporation (NYSE: BAC) and prior to that, was with Cowen & Company (NASDAQ: COWN). Ms. Ellingson holds an MBA in Finance from the University of Connecticut and a Bachelor of Arts degree from the University of Rhode Island.
- Amy DuRoss
-
Amy DuRoss，自2021年4月起担任公司治理和提名委员会董事和成员，并担任薪酬委员会主席。杜罗斯女士曾担任医疗保健技术公司Vineti，Inc.的首席执行官，从她于2016年4月共同创立Vineti到2022年3月。DuRoss女士带领Vineti及其软件即服务平台走在支持细胞和基因疗法制造、交付和患者随访的创新前沿。在共同创立Vineti之前，DuRoss女士专注于为GE Ventures创建医疗保健新业务，GE Ventures是通用电气（纽约证券交易所代码：GE）的风险投资子公司，2013年5月至2017年5月担任董事总经理。在加入GE之前，杜罗斯女士是Navigenics公司的首席商务官，该公司是一家基因组学公司，于2012年出售给生命科学。杜罗斯女士是第71号提案的联合创始人和执行董事，该提案是2004年通过的加州干细胞研究计划，也是最终成立的州拨款监督机构的办公室主任。杜罗斯女士被阿斯彭研究所评为2016年健康创新研究员。杜罗斯女士还担任ARM细胞和基因医学基金会董事会成员。杜罗斯女士拥有斯坦福大学的MBA、英语硕士学位和英语文学学士学位。
Amy DuRoss,has served as Lead Independent Director of Biolife Solutions, Inc. Board of Directors since August 2023 and member of Biolife Solutions, Inc. Governance and Nominating Committee and as Chair of Biolife Solutions, Inc. Compensation Committee since April 2021. Since May 2025, Ms. DuRoss has served at Mayo Clinic as a MayoVenture Partner, where she leads enterprise-wide efforts in venture creation, strategic capital markets, institutional spinouts, and the commercialization of transformative science and care delivery models. She works across the Mayo ecosystem to build and scale the next generation of healthcare companies - from advanced cell and gene-based therapeutics and diagnostics to enabling platforms and digital health. Ms. DuRoss previously served as Chief Executive Officer of Vineti, Inc., a healthcare technology company, from the time that she co-founded Vineti in April 2016 through March 2022. Ms. DuRoss led Vineti and its software as a service platform to the forefront of innovation supporting cell and gene therapy manufacturing, delivery and patient follow up. Before co-founding Vineti, Ms. DuRoss focused on healthcare new business creation for GE Ventures, a venture capital subsidiary of General Electric (NYSE: GE), serving as a Managing Director from May 2013 to May 2017. Prior to GE, Ms. DuRoss was Chief Business Officer at Navigenics, Inc., a genomics company sold to Life Technologies Corporation in 2012. Ms. DuRoss was Co-founder and Executive Director of Proposition 71, California's stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Ms. DuRoss was named a 2016 Health Innovator Fellow by the Aspen Institute. Ms. DuRoss also serves as a member of the Board of Directors for the ARM Foundation for Cell and Gene Medicine. Ms. DuRoss holds an MBA, Masters degree in English, and Bachelors of Arts degree in English from Stanford University. - Amy DuRoss，自2021年4月起担任公司治理和提名委员会董事和成员，并担任薪酬委员会主席。杜罗斯女士曾担任医疗保健技术公司Vineti，Inc.的首席执行官，从她于2016年4月共同创立Vineti到2022年3月。DuRoss女士带领Vineti及其软件即服务平台走在支持细胞和基因疗法制造、交付和患者随访的创新前沿。在共同创立Vineti之前，DuRoss女士专注于为GE Ventures创建医疗保健新业务，GE Ventures是通用电气（纽约证券交易所代码：GE）的风险投资子公司，2013年5月至2017年5月担任董事总经理。在加入GE之前，杜罗斯女士是Navigenics公司的首席商务官，该公司是一家基因组学公司，于2012年出售给生命科学。杜罗斯女士是第71号提案的联合创始人和执行董事，该提案是2004年通过的加州干细胞研究计划，也是最终成立的州拨款监督机构的办公室主任。杜罗斯女士被阿斯彭研究所评为2016年健康创新研究员。杜罗斯女士还担任ARM细胞和基因医学基金会董事会成员。杜罗斯女士拥有斯坦福大学的MBA、英语硕士学位和英语文学学士学位。
- Amy DuRoss,has served as Lead Independent Director of Biolife Solutions, Inc. Board of Directors since August 2023 and member of Biolife Solutions, Inc. Governance and Nominating Committee and as Chair of Biolife Solutions, Inc. Compensation Committee since April 2021. Since May 2025, Ms. DuRoss has served at Mayo Clinic as a MayoVenture Partner, where she leads enterprise-wide efforts in venture creation, strategic capital markets, institutional spinouts, and the commercialization of transformative science and care delivery models. She works across the Mayo ecosystem to build and scale the next generation of healthcare companies - from advanced cell and gene-based therapeutics and diagnostics to enabling platforms and digital health. Ms. DuRoss previously served as Chief Executive Officer of Vineti, Inc., a healthcare technology company, from the time that she co-founded Vineti in April 2016 through March 2022. Ms. DuRoss led Vineti and its software as a service platform to the forefront of innovation supporting cell and gene therapy manufacturing, delivery and patient follow up. Before co-founding Vineti, Ms. DuRoss focused on healthcare new business creation for GE Ventures, a venture capital subsidiary of General Electric (NYSE: GE), serving as a Managing Director from May 2013 to May 2017. Prior to GE, Ms. DuRoss was Chief Business Officer at Navigenics, Inc., a genomics company sold to Life Technologies Corporation in 2012. Ms. DuRoss was Co-founder and Executive Director of Proposition 71, California's stem cell research initiative passed in 2004, as well as Chief of Staff at the resulting state grant oversight agency. Ms. DuRoss was named a 2016 Health Innovator Fellow by the Aspen Institute. Ms. DuRoss also serves as a member of the Board of Directors for the ARM Foundation for Cell and Gene Medicine. Ms. DuRoss holds an MBA, Masters degree in English, and Bachelors of Arts degree in English from Stanford University.
- Joydeep Goswami
-
Joydeep Goswami，自2021年10月起担任公司审计委员会董事和成员，并担任提名和治理委员会主席。他目前担任Illumina（一家生物技术公司）的首席财务官、首席战略和企业发展官（2019年9月以来）。作为Illumina执行领导层的成员，他负责推动规划、战略合作伙伴关系和收购。在加入Illumina之前，他曾担任Thermo Fisher Scientific的临床下一代测序（NGS）和肿瘤学业务部门的总裁，在那里他监督推动NGS在临床肿瘤学、研究和生殖健康方面的采用。他曾担任制药/生物技术、诊断和研究工具连续体的高级领导职务，此前曾任职于Life Technologies和Invitrogen等公司，以及Thermo Fisher Scientific。他领导过多个职能部门的团队，包括销售、市场营销、研发和其他支持职能部门。他曾在Thermo Fisher Scientific担任亚太区和日本总裁，并在Invitrogen公司创建了干细胞和再生医学业务部门。此外，他在McKinsey工作了五年，在那里他专门从事制药、医疗技术和技术公司的战略。Goswami先生持有麻省理工学院化学工程硕士、博士学位和工商管理硕士学位，以及印度理工学院化学工程学士学位。
Joydeep Goswami,serves as President and Chief Executive Officer of LGC Group, an international life sciences measurement and tools company. Prior to his appointment as CEO of LGC Group in January 2025, Dr. Goswami served as an Advisor to Illumina, Inc. ("Illumina"), a life sciences tools and diagnostics company, between April 2024 to December 2024. From February 2023 and April 2024, Dr. Goswami also served as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina. During his service on the executive leadership team at Illumina, Dr. Goswami was responsible for driving planning, strategic partnerships, and acquisitions. Prior to Illumina, Dr. Goswami served from July 2016 through August 2019 as the President of the Clinical Next-Generation Sequencing (NGS) and Oncology business unit of Thermo Fisher Scientific Inc. ("Thermo Fisher Scientific"), where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Dr. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies Corp. ("Life Technologies") from July 2008 through August 2013 and Invitrogen Corp. ("Invitrogen") from December 2003 through July 2008, in addition to other roles at Thermo Fisher Scientificfrom September 2013 through July 2016. He has led teams across various functions, including sales, marketing, R&D and other support functions. Dr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies. Dr. Goswami holds his MS, PhD in Chemical Engineering, and MBA from MIT and a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology. - Joydeep Goswami，自2021年10月起担任公司审计委员会董事和成员，并担任提名和治理委员会主席。他目前担任Illumina（一家生物技术公司）的首席财务官、首席战略和企业发展官（2019年9月以来）。作为Illumina执行领导层的成员，他负责推动规划、战略合作伙伴关系和收购。在加入Illumina之前，他曾担任Thermo Fisher Scientific的临床下一代测序（NGS）和肿瘤学业务部门的总裁，在那里他监督推动NGS在临床肿瘤学、研究和生殖健康方面的采用。他曾担任制药/生物技术、诊断和研究工具连续体的高级领导职务，此前曾任职于Life Technologies和Invitrogen等公司，以及Thermo Fisher Scientific。他领导过多个职能部门的团队，包括销售、市场营销、研发和其他支持职能部门。他曾在Thermo Fisher Scientific担任亚太区和日本总裁，并在Invitrogen公司创建了干细胞和再生医学业务部门。此外，他在McKinsey工作了五年，在那里他专门从事制药、医疗技术和技术公司的战略。Goswami先生持有麻省理工学院化学工程硕士、博士学位和工商管理硕士学位，以及印度理工学院化学工程学士学位。
- Joydeep Goswami,serves as President and Chief Executive Officer of LGC Group, an international life sciences measurement and tools company. Prior to his appointment as CEO of LGC Group in January 2025, Dr. Goswami served as an Advisor to Illumina, Inc. ("Illumina"), a life sciences tools and diagnostics company, between April 2024 to December 2024. From February 2023 and April 2024, Dr. Goswami also served as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina. During his service on the executive leadership team at Illumina, Dr. Goswami was responsible for driving planning, strategic partnerships, and acquisitions. Prior to Illumina, Dr. Goswami served from July 2016 through August 2019 as the President of the Clinical Next-Generation Sequencing (NGS) and Oncology business unit of Thermo Fisher Scientific Inc. ("Thermo Fisher Scientific"), where he oversaw efforts that drove the adoption of NGS in clinical oncology, research and reproductive health. Dr. Goswami has held senior leadership roles across the pharma/biotech, diagnostics and research tool continuum, previously serving at companies such as Life Technologies Corp. ("Life Technologies") from July 2008 through August 2013 and Invitrogen Corp. ("Invitrogen") from December 2003 through July 2008, in addition to other roles at Thermo Fisher Scientificfrom September 2013 through July 2016. He has led teams across various functions, including sales, marketing, R&D and other support functions. Dr. Goswami served as President, Asia Pacific and Japan while at Thermo Fisher Scientific and created the Stem Cells and Regenerative Medicine Business Unit at Invitrogen. Additionally, he spent five years at McKinsey, where he specialized in strategy for pharmaceutical, medical technology and technology companies. Dr. Goswami holds his MS, PhD in Chemical Engineering, and MBA from MIT and a Bachelor's degree in Chemical Engineering from the Indian Institute of Technology.
- Tim Moore
-
Tim Moore自2022年9月起担任公司薪酬、提名和治理委员会的董事和成员。摩尔先生担任Instil Bio的首席运营官至2022年12月，该公司是一家专注于实体瘤的TIL细胞治疗公司。摩尔还曾在2019年10月至2022年9月期间担任PACT Pharma的总裁兼首席运营官。在加入PACT之前，他自2016年3月起担任吉利德公司Kite的技术运营执行副总裁。在此期间，Moore先生负责监督Yescarta 的推出过程开发、制造、质量和供应链，Yescarta 是首批被开发、制造和商业化的CAR T疗法之一，以及Kite管道的推进。此外，摩尔还在全球范围内扩大了生物制药业务，为美国、欧盟以及亚洲的主要合作伙伴提供服务和支持。在加入Kite之前，Moore先生曾担任Genentech，Inc.的高级副总裁兼全球生物技术运营主管，并自2010年起担任Genentech执行委员会成员。在担任这一职务期间，摩尔先生负责监督10个内部站点和37个合同制造组织的7500多名专业人员的全球领导工作，以及20多个生物制品家族的全球制造和端到端质量供应业绩。在此之前，摩尔曾在2007年至2010年担任基因泰克全球供应链和全球工程高级副总裁。此前，穆尔曾担任ZLB Behring（前身为Aventis Behring）的运营副总裁。他目前是ISPE、PDA的成员，也是BioPhorum执行委员会的成员，并担任Cerus的董事会成员。摩尔先生在塔尔萨大学获得化学工程学士学位，在西北大学获得工程管理硕士学位。
Tim Moore,has served as a director and member of BioLife Solutions, Inc. Compensation and Governance and Nominating Committees since September 2022. He has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Mr. Moore served as Executive Vice President, Chief Technical Operations at Allogene Therapeutics, Inc. through February 2025, an allogeneic company for CAR-T cell therapy. Mr. Moore also served as COO of Instil Bio through December 2022, a TIL cell therapy company focused on solid tumors. Mr. Moore also served as the President and COO at PACT Pharma from October 2019 through September 2022. Prior to joining PACT, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia. Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech's Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University. - Tim Moore自2022年9月起担任公司薪酬、提名和治理委员会的董事和成员。摩尔先生担任Instil Bio的首席运营官至2022年12月，该公司是一家专注于实体瘤的TIL细胞治疗公司。摩尔还曾在2019年10月至2022年9月期间担任PACT Pharma的总裁兼首席运营官。在加入PACT之前，他自2016年3月起担任吉利德公司Kite的技术运营执行副总裁。在此期间，Moore先生负责监督Yescarta 的推出过程开发、制造、质量和供应链，Yescarta 是首批被开发、制造和商业化的CAR T疗法之一，以及Kite管道的推进。此外，摩尔还在全球范围内扩大了生物制药业务，为美国、欧盟以及亚洲的主要合作伙伴提供服务和支持。在加入Kite之前，Moore先生曾担任Genentech，Inc.的高级副总裁兼全球生物技术运营主管，并自2010年起担任Genentech执行委员会成员。在担任这一职务期间，摩尔先生负责监督10个内部站点和37个合同制造组织的7500多名专业人员的全球领导工作，以及20多个生物制品家族的全球制造和端到端质量供应业绩。在此之前，摩尔曾在2007年至2010年担任基因泰克全球供应链和全球工程高级副总裁。此前，穆尔曾担任ZLB Behring（前身为Aventis Behring）的运营副总裁。他目前是ISPE、PDA的成员，也是BioPhorum执行委员会的成员，并担任Cerus的董事会成员。摩尔先生在塔尔萨大学获得化学工程学士学位，在西北大学获得工程管理硕士学位。
- Tim Moore,has served as a director and member of BioLife Solutions, Inc. Compensation and Governance and Nominating Committees since September 2022. He has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. Mr. Moore served as Executive Vice President, Chief Technical Operations at Allogene Therapeutics, Inc. through February 2025, an allogeneic company for CAR-T cell therapy. Mr. Moore also served as COO of Instil Bio through December 2022, a TIL cell therapy company focused on solid tumors. Mr. Moore also served as the President and COO at PACT Pharma from October 2019 through September 2022. Prior to joining PACT, he served as Executive Vice President, Technical Operations at Kite, a Gilead Company, since March of 2016. During this time Mr. Moore was responsible for overseeing the process development, manufacturing, quality and supply chain for the launch of Yescarta, one of the first CAR T therapies to be developed, manufactured and commercialized, as well as advancement of the Kite pipeline. In addition, Mr. Moore globally expanded biopharmaceutical operations to serve and support the US, EU, as well as key partners in Asia. Prior to Kite, Mr. Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee since 2010. In this role, Mr. Moore oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families. Prior to that, Mr. Moore was Genentech's Senior Vice President, Global Supply Chain and Global Engineering from 2007 to 2010. Previously, Mr. Moore served as Vice President, Operations at ZLB Behring (formerly Aventis Behring). He is currently a member of ISPE, PDA and has been a part of the Executive Committee of BioPhorum and serves as a Board member for Cerus. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
- Cathy Coste
-
Cathy Coste，自2023年1月起担任首席人力资源官。此前，Aebersold女士自2021年1月起担任全球人力资源副总裁，并自2020年2月起担任全球人力资源与行政高级总监。在担任该职务期间，Aebersold女士负责监督员工关系、人才获取、福利、薪酬、辅导、培训和发展、政策以及数据管理等领域的人力资源项目。在加入公司之前，Aebersold女士曾在多家公司担任人力资源职务，包括医疗保健解决方案提供商MCG Health（2016-2020年，最近担任人力资源和行政主管）、医疗设备制造商Spacelabs Healthcare（2014-2016年、2012-2013年，最近担任人力资源高级经理）、移动通信公司T-Mobile（2013-2013年，最近担任人力资源经理）、儿童医院西雅图儿童医院（2009-2012年，最近担任人力资源咨询经理）以及生物技术/制药公司ZymoGenetics，Inc.（2004-2009年，最近担任人力资源经理）。
Cathy Coste,has been Chief Human Resources Officer since January 2023. Previously, Ms. Aebersold was Vice President, Global Human Resources since January 2021 and served as the Senior Director, Global Human Resources & Administration since February 2020. In that role, Ms. Aebersold oversaw human resources programs in the areas of employee relations, talent acquisition, benefits, compensation, coaching, training and development, policy, and data management. Prior to joining the Company, Ms. Aebersold served in a variety of human resources roles with companies including MCG Health, a healthcare solutions provider (2016-2020, most recently as Head of Human Resources and Administration), Spacelabs Healthcare, a manufacturer of medical equipment (2014-2016, 2012-2013, most recently as Senior Manager, Human Resources), T-Mobile, a mobile communication company, (2013-2013, most recently as Human Resource Manager), Seattle Children's Hospital, a children's hospital (2009-2012, most recently as Manager, Human Resources Consulting), and ZymoGenetics, Inc., a biotechnology/pharmaceutical company (2004-2009, most recently as Human Resources Manager). - Cathy Coste，自2023年1月起担任首席人力资源官。此前，Aebersold女士自2021年1月起担任全球人力资源副总裁，并自2020年2月起担任全球人力资源与行政高级总监。在担任该职务期间，Aebersold女士负责监督员工关系、人才获取、福利、薪酬、辅导、培训和发展、政策以及数据管理等领域的人力资源项目。在加入公司之前，Aebersold女士曾在多家公司担任人力资源职务，包括医疗保健解决方案提供商MCG Health（2016-2020年，最近担任人力资源和行政主管）、医疗设备制造商Spacelabs Healthcare（2014-2016年、2012-2013年，最近担任人力资源高级经理）、移动通信公司T-Mobile（2013-2013年，最近担任人力资源经理）、儿童医院西雅图儿童医院（2009-2012年，最近担任人力资源咨询经理）以及生物技术/制药公司ZymoGenetics，Inc.（2004-2009年，最近担任人力资源经理）。
- Cathy Coste,has been Chief Human Resources Officer since January 2023. Previously, Ms. Aebersold was Vice President, Global Human Resources since January 2021 and served as the Senior Director, Global Human Resources & Administration since February 2020. In that role, Ms. Aebersold oversaw human resources programs in the areas of employee relations, talent acquisition, benefits, compensation, coaching, training and development, policy, and data management. Prior to joining the Company, Ms. Aebersold served in a variety of human resources roles with companies including MCG Health, a healthcare solutions provider (2016-2020, most recently as Head of Human Resources and Administration), Spacelabs Healthcare, a manufacturer of medical equipment (2014-2016, 2012-2013, most recently as Senior Manager, Human Resources), T-Mobile, a mobile communication company, (2013-2013, most recently as Human Resource Manager), Seattle Children's Hospital, a children's hospital (2009-2012, most recently as Manager, Human Resources Consulting), and ZymoGenetics, Inc., a biotechnology/pharmaceutical company (2004-2009, most recently as Human Resources Manager).
- Tony Hunt
-
Tony Hunt，自2025年1月起担任BioLife Solutions公司董事、审计委员会成员，自2025年3月起担任BioLife Solutions公司薪酬委员会成员。Hunt先生自2024年9月起担任Repligen Corporation或雷普里根（纳斯达克股票代码：RGEN）的执行主席。在被任命为雷普里根执行主席之前，Hunt先生自2015年5月起担任雷普里根的首席执行官和董事会成员，并于2014年5月加入雷普里根，担任首席运营官。在加入雷普里根之前，Hunt先生是生命科学或生命技术公司的生物生产总裁，该公司是一家全球生命科学公司，于2014年被赛默飞世尔收购。他于2008年加入Life Technologies，担任BioProduction色谱和Pharma Analytics总经理，之后于2011年被任命为BioProduction总裁。从2000年到2008年，Hunt先生在Applied Biosystems担任制药项目高级总监，在那里他启动了Pharma Analytics业务，该业务于2008年成为Life Technologies生物生产平台的一部分。Hunt先生还在一家上市公司—— 908 Devices Inc.（NASDAQ：MASS）的董事会任职。亨特先生获得了爱尔兰戈尔韦大学学院的微生物学学士学位和生物技术硕士学位，以及波士顿大学管理学院的工商管理硕士学位。
Tony Hunt,has served as a director and member of BioLife Solutions, Inc. Audit Committee since January 2025, and a member of BioLife Solutions, Inc. Compensation Committee since March 2025. Mr. Hunt has served as Executive Chairman of Repligen Corporation, or Repligen (NASDAQ: RGEN), since September 2024. Prior to being named Executive Chairman of Repligen, Mr. Hunt served as Chief Executive Officer and as a member of the board of directors of Repligen since May 2015, having joined Repligen in May 2014 as Chief Operating Officer. Prior to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies Corporation, or Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems s Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. (NASDAQ: MASS). Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and a M.B.A. from Boston University School of Management. - Tony Hunt，自2025年1月起担任BioLife Solutions公司董事、审计委员会成员，自2025年3月起担任BioLife Solutions公司薪酬委员会成员。Hunt先生自2024年9月起担任Repligen Corporation或雷普里根（纳斯达克股票代码：RGEN）的执行主席。在被任命为雷普里根执行主席之前，Hunt先生自2015年5月起担任雷普里根的首席执行官和董事会成员，并于2014年5月加入雷普里根，担任首席运营官。在加入雷普里根之前，Hunt先生是生命科学或生命技术公司的生物生产总裁，该公司是一家全球生命科学公司，于2014年被赛默飞世尔收购。他于2008年加入Life Technologies，担任BioProduction色谱和Pharma Analytics总经理，之后于2011年被任命为BioProduction总裁。从2000年到2008年，Hunt先生在Applied Biosystems担任制药项目高级总监，在那里他启动了Pharma Analytics业务，该业务于2008年成为Life Technologies生物生产平台的一部分。Hunt先生还在一家上市公司—— 908 Devices Inc.（NASDAQ：MASS）的董事会任职。亨特先生获得了爱尔兰戈尔韦大学学院的微生物学学士学位和生物技术硕士学位，以及波士顿大学管理学院的工商管理硕士学位。
- Tony Hunt,has served as a director and member of BioLife Solutions, Inc. Audit Committee since January 2025, and a member of BioLife Solutions, Inc. Compensation Committee since March 2025. Mr. Hunt has served as Executive Chairman of Repligen Corporation, or Repligen (NASDAQ: RGEN), since September 2024. Prior to being named Executive Chairman of Repligen, Mr. Hunt served as Chief Executive Officer and as a member of the board of directors of Repligen since May 2015, having joined Repligen in May 2014 as Chief Operating Officer. Prior to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies Corporation, or Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems s Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc. (NASDAQ: MASS). Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and a M.B.A. from Boston University School of Management.
- Roderick de Greef
-
Roderick de Greef，自2021年11月起担任BioLife的总裁兼首席运营官，直到他于2023年1月3日退休，并被任命为董事会董事。此前，de Greef先生于2016年5月至2021年11月被任命为首席财务官，并于2019年12月至2021年5月被任命为首席运营官。他于2016年3月被任命为临时首席财务官和临时秘书。他从2000年6月到2013年11月担任公司董事，并从2007年7月到2011年8月为公司提供战略和财务咨询服务。自2022年11月起，他担任Upper Connecticut Valley Hospital（New Hampshire北部的一家非营利性农村医院）的董事。自2020年12月以来，他一直担任Sirona Medical Technologies（一家心脏电生理公司）的董事。从2019年2月至2021年1月，de Greef先生担任印度尼西亚能源有限公司（一家石油和天然气勘探和生产公司）董事会审计委员会主席。他曾任职于Pareteum Corporation。从2015年9月到2017年9月，以及从2008年1月到2011年10月，担任董事、审计委员会主席、提名和公司治理委员会和薪酬委员会成员。从2013年11月到2014年10月，他担任Cambridge Cardiac Technologies, Inc. （Cambridge Heart, Inc.的私人继承者）的总裁和唯一董事。2008年11月至2013年10月，他担任Cambridge Heart, Inc.（非侵入性诊断心脏病学产品的制造商）的董事会主席。2003年11月至2013年5月，他担任Endologix, Inc.的董事、审计委员会成员和薪酬委员会主席。2001年至2006年，他担任纳斯达克上市公司Cardiac Science, Inc.的执行副总裁兼首席财务官，该公司在2004年被Deloitte & Touche的快速500强上市公司评为北美增长最快的科技公司第四名。他持有Oregon大学的工商管理硕士学位，以及San Francisco State大学的经济学和国际关系学士学位。
Roderick de Greef,has been Chief Executive Officer and Chairman of the Board since October 2023 at BioLife. Previously, Mr. de Greef began serving as a director of the Board in January 2023, prior to which he served as President and Chief Operating Officer from November 2021 until he retired on January 3, 2023. Mr. de Greef was appointed Chief Operating Officer from December 2019 to May 2021 after his appointment as Chief Financial Officer from May 2016 to November 2021. He also served as interim Chief Financial Officer and interim Secretary from March 2016 through May 2016. Mr. de Greef served as a director of the Company from June 2000 through November 2013 and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since November 2022, Mr. de Greef has served as a director of the Upper Connecticut Valley Hospital, a non-profit, rural hospital in northern New Hampshire. Since December 2020, Mr. de Greef has served as a director of Sirona Medical Technologies, a cardia electrophysiology company. From February 2019 to January 2021, Mr. de Greef served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation, a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of Cardiac Science, Inc. (which went private in September 2005), which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. Mr. de Greef received his Master of Business Administration degree from the University of Oregon, and a Bachelor of Arts in Economics and International Relations from San Francisco State University. - Roderick de Greef，自2021年11月起担任BioLife的总裁兼首席运营官，直到他于2023年1月3日退休，并被任命为董事会董事。此前，de Greef先生于2016年5月至2021年11月被任命为首席财务官，并于2019年12月至2021年5月被任命为首席运营官。他于2016年3月被任命为临时首席财务官和临时秘书。他从2000年6月到2013年11月担任公司董事，并从2007年7月到2011年8月为公司提供战略和财务咨询服务。自2022年11月起，他担任Upper Connecticut Valley Hospital（New Hampshire北部的一家非营利性农村医院）的董事。自2020年12月以来，他一直担任Sirona Medical Technologies（一家心脏电生理公司）的董事。从2019年2月至2021年1月，de Greef先生担任印度尼西亚能源有限公司（一家石油和天然气勘探和生产公司）董事会审计委员会主席。他曾任职于Pareteum Corporation。从2015年9月到2017年9月，以及从2008年1月到2011年10月，担任董事、审计委员会主席、提名和公司治理委员会和薪酬委员会成员。从2013年11月到2014年10月，他担任Cambridge Cardiac Technologies, Inc. （Cambridge Heart, Inc.的私人继承者）的总裁和唯一董事。2008年11月至2013年10月，他担任Cambridge Heart, Inc.（非侵入性诊断心脏病学产品的制造商）的董事会主席。2003年11月至2013年5月，他担任Endologix, Inc.的董事、审计委员会成员和薪酬委员会主席。2001年至2006年，他担任纳斯达克上市公司Cardiac Science, Inc.的执行副总裁兼首席财务官，该公司在2004年被Deloitte & Touche的快速500强上市公司评为北美增长最快的科技公司第四名。他持有Oregon大学的工商管理硕士学位，以及San Francisco State大学的经济学和国际关系学士学位。
- Roderick de Greef,has been Chief Executive Officer and Chairman of the Board since October 2023 at BioLife. Previously, Mr. de Greef began serving as a director of the Board in January 2023, prior to which he served as President and Chief Operating Officer from November 2021 until he retired on January 3, 2023. Mr. de Greef was appointed Chief Operating Officer from December 2019 to May 2021 after his appointment as Chief Financial Officer from May 2016 to November 2021. He also served as interim Chief Financial Officer and interim Secretary from March 2016 through May 2016. Mr. de Greef served as a director of the Company from June 2000 through November 2013 and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since November 2022, Mr. de Greef has served as a director of the Upper Connecticut Valley Hospital, a non-profit, rural hospital in northern New Hampshire. Since December 2020, Mr. de Greef has served as a director of Sirona Medical Technologies, a cardia electrophysiology company. From February 2019 to January 2021, Mr. de Greef served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation, a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of Cardiac Science, Inc. (which went private in September 2005), which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. Mr. de Greef received his Master of Business Administration degree from the University of Oregon, and a Bachelor of Arts in Economics and International Relations from San Francisco State University.
高管简历
中英对照 | 中文 | 英文- Todd Berard
Todd Berard，一直担任营销副总裁（2015年2月以来），负责企业品牌、产品品牌、营销和启动策略和产品管理。他也担任所有产品（包括biologistex）发布的管理和增长的关键团队成员。担任营销副总裁之前，他曾担任高级营销董事（2014年7月以来）。任职BioLife公司之前，他曾担任Verathon Medical公司（Roper公司的部门）的营销董事（从2010年9月到2014年7月），负责监管6个医疗设备品牌的投资组合的全球营销、产品开发和产品发布策略。他也曾管理产品开发的所有战略合作伙伴关系，并帮助指导组织。Verathon公司的2014年全球销量大约180美元。他负责监督12人的创意和产品管理团队。他负责所有的全球营销计划和活动、策略、产品组合管理和战略规划。他拥有20年以上的生命科学、医疗保健和技术经验，任职全球领导人和小技术创业公司，包括Washington大学School of Medicine、DuPont、Medtronic。他持有Vermont大学的生物化学科学学士学位，以及Washington大学Foster School of Business的工商管理硕士学位。
Todd Berard,has been Chief Commercial Officer since December 2019. Before his appointment as Chief Commercial Officer, Mr. Berard had served as Vice President of Marketing since February 2015 and Senior Director of Marketing since July 2014. Previous to BioLife, Mr. Berard served as Director of Marketing at Verathon Medical; a division of Roper Inc., from September 2010 until July 2014, overseeing the global marketing, product development, and product launch strategies for a portfolio of six medical device brands. He also managed all strategic partnerships for product development and helped guide the organization through several key product launches and the corporate acquisition. At Verathon, Mr. Berard oversaw a creative and product management team of 12. Responsibilities included all global marketing initiatives and campaigns, strategy, product portfolio management, and strategic planning. He has over twenty years of experience in life sciences, health care, medical devices, and technology; working for both global leaders and small technology startups, including the University of Washington School of Medicine, DuPont, and Medtronic. He has a Bachelor of Science Degree in Biochemistry from the University of Vermont and an MBA from the University of Washington Foster School of Business.- Todd Berard，一直担任营销副总裁（2015年2月以来），负责企业品牌、产品品牌、营销和启动策略和产品管理。他也担任所有产品（包括biologistex）发布的管理和增长的关键团队成员。担任营销副总裁之前，他曾担任高级营销董事（2014年7月以来）。任职BioLife公司之前，他曾担任Verathon Medical公司（Roper公司的部门）的营销董事（从2010年9月到2014年7月），负责监管6个医疗设备品牌的投资组合的全球营销、产品开发和产品发布策略。他也曾管理产品开发的所有战略合作伙伴关系，并帮助指导组织。Verathon公司的2014年全球销量大约180美元。他负责监督12人的创意和产品管理团队。他负责所有的全球营销计划和活动、策略、产品组合管理和战略规划。他拥有20年以上的生命科学、医疗保健和技术经验，任职全球领导人和小技术创业公司，包括Washington大学School of Medicine、DuPont、Medtronic。他持有Vermont大学的生物化学科学学士学位，以及Washington大学Foster School of Business的工商管理硕士学位。
- Todd Berard,has been Chief Commercial Officer since December 2019. Before his appointment as Chief Commercial Officer, Mr. Berard had served as Vice President of Marketing since February 2015 and Senior Director of Marketing since July 2014. Previous to BioLife, Mr. Berard served as Director of Marketing at Verathon Medical; a division of Roper Inc., from September 2010 until July 2014, overseeing the global marketing, product development, and product launch strategies for a portfolio of six medical device brands. He also managed all strategic partnerships for product development and helped guide the organization through several key product launches and the corporate acquisition. At Verathon, Mr. Berard oversaw a creative and product management team of 12. Responsibilities included all global marketing initiatives and campaigns, strategy, product portfolio management, and strategic planning. He has over twenty years of experience in life sciences, health care, medical devices, and technology; working for both global leaders and small technology startups, including the University of Washington School of Medicine, DuPont, and Medtronic. He has a Bachelor of Science Degree in Biochemistry from the University of Vermont and an MBA from the University of Washington Foster School of Business.
- Karen Foster
Karen Foster自2019年12月起担任首席质量官。在被任命为首席质量官之前，福斯特女士自2016年4月起担任运营部Vice President。从2003年到2016年初，福斯特女士担任Viacord，LLC实验室运营Vice President和现场负责人，该公司是一家家庭脐带血库，也是PerkinElmer Inc.的子公司。在25年的职业生涯中，Foster女士为多家公司管理制造和质量运营，包括Viacord，Pfizer，Inc.（前身为Pharmacia Corporation）和Amersham Pharmacia Biotech，Inc.（前身为Pharmacia Biotech，Inc.）。她持有威斯康星大学密尔沃基分校（the University of Wisconsin-Milwaukee）（运营管理专业）的工商管理硕士学位、威斯康星大学密尔沃基分校（the University of Wisconsin-Milwaukee）的动物学硕士学位（微生物学专业）和密歇根科技大学（Michigan Technological University）的生物科学学士学位。
Karen Foster,has been Chief Quality Officer since December 2019 and became Chief Quality and Operations Officer as of January 2024. Before her appointment as Chief Quality Officer, Ms. Foster had served as Vice President, Operations since April 2016. From 2003 to early 2016, Ms. Foster was Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank, and subsidiary of PerkinElmer Inc. Over a 25-year career, Ms. Foster has managed manufacturing and quality operations in several capacities for companies including ViaCord, Pfizer, Inc. (formerly Pharmacia Corporation) and Amersham Pharmacia Biotech, Inc. (formerly Phamacia Biotech, Inc.). She holds an MBA from the University of Wisconsin-Milwaukee (specialization in Operations Management), an M.S. in Zoology from University of Wisconsin-Milwaukee (specialization in Microbiology) and a B.S. in Biological Sciences from Michigan Technological University.- Karen Foster自2019年12月起担任首席质量官。在被任命为首席质量官之前，福斯特女士自2016年4月起担任运营部Vice President。从2003年到2016年初，福斯特女士担任Viacord，LLC实验室运营Vice President和现场负责人，该公司是一家家庭脐带血库，也是PerkinElmer Inc.的子公司。在25年的职业生涯中，Foster女士为多家公司管理制造和质量运营，包括Viacord，Pfizer，Inc.（前身为Pharmacia Corporation）和Amersham Pharmacia Biotech，Inc.（前身为Pharmacia Biotech，Inc.）。她持有威斯康星大学密尔沃基分校（the University of Wisconsin-Milwaukee）（运营管理专业）的工商管理硕士学位、威斯康星大学密尔沃基分校（the University of Wisconsin-Milwaukee）的动物学硕士学位（微生物学专业）和密歇根科技大学（Michigan Technological University）的生物科学学士学位。
- Karen Foster,has been Chief Quality Officer since December 2019 and became Chief Quality and Operations Officer as of January 2024. Before her appointment as Chief Quality Officer, Ms. Foster had served as Vice President, Operations since April 2016. From 2003 to early 2016, Ms. Foster was Vice President of Laboratory Operations and Site Leader at ViaCord, LLC, a family cord blood bank, and subsidiary of PerkinElmer Inc. Over a 25-year career, Ms. Foster has managed manufacturing and quality operations in several capacities for companies including ViaCord, Pfizer, Inc. (formerly Pharmacia Corporation) and Amersham Pharmacia Biotech, Inc. (formerly Phamacia Biotech, Inc.). She holds an MBA from the University of Wisconsin-Milwaukee (specialization in Operations Management), an M.S. in Zoology from University of Wisconsin-Milwaukee (specialization in Microbiology) and a B.S. in Biological Sciences from Michigan Technological University.
- Troy Wichterman
Troy Wichterman，自2021年11月起担任首席财务官。在被任命为首席财务官之前，Wichterman先生自2019年11月起担任公司财务副总裁。在担任这一职务期间，Wichterman先生负责监督财务和会计组织在以下领域的工作：整合收购的业务、收购的尽职调查和交易结构、SEC报告、财务规划和分析、运营财务和审计合规。Wichterman先生还于2016年6月至2019年11月担任财务规划和分析主任，并于2015年2月至2016年6月担任财务分析师。在加入公司之前，他最近于2013年1月至2014年9月在公共医疗保健房地产投资信托基金芬塔担任高级财务分析师。在加入芬塔之前，他最近于2009年6月至2013年1月担任私人股本房地产投资信托公司Heitman的高级投资组合分析师，并于2008年至2009年在芝加哥的普华永道担任审计助理。Wichterman先生是注册会计师（非在职），拥有威斯康星大学麦迪逊分校工商管理学士学位和会计学硕士学位。
Troy Wichterman,has been Chief Financial Officer since November 2021. Before his appointment as Chief Financial Officer, Mr. Wichterman served as the Company's Vice President, Finance since November 2019. In that role, Mr. Wichterman oversaw the finance and accounting organization in the areas of integrating acquired businesses, acquisition due diligence and deal structure, SEC reporting, financial planning and analysis, operational finance, and audit compliance. Mr. Wichterman also served as Director of Financial Planning and Analysis from June 2016 to November 2019 and Financial Analyst from February 2015 to June 2016. Prior to joining the Company, he was most recently a Senior Financial Analyst, Acquisitions at Ventas, a public healthcare REIT, from January 2013 to September 2014. Prior to Ventas, he was most recently a Senior Portfolio Analyst at Heitman, a private equity REIT, from June 2009 – January 2013 and began his career as an Auditing Associate at PwC in Chicago from 2008 to 2009. Mr. Wichterman is a CPA (inactive) and holds a Bachelor of Business Administration degree and a Master of Accountancy degree from the University of Wisconsin – Madison.- Troy Wichterman，自2021年11月起担任首席财务官。在被任命为首席财务官之前，Wichterman先生自2019年11月起担任公司财务副总裁。在担任这一职务期间，Wichterman先生负责监督财务和会计组织在以下领域的工作：整合收购的业务、收购的尽职调查和交易结构、SEC报告、财务规划和分析、运营财务和审计合规。Wichterman先生还于2016年6月至2019年11月担任财务规划和分析主任，并于2015年2月至2016年6月担任财务分析师。在加入公司之前，他最近于2013年1月至2014年9月在公共医疗保健房地产投资信托基金芬塔担任高级财务分析师。在加入芬塔之前，他最近于2009年6月至2013年1月担任私人股本房地产投资信托公司Heitman的高级投资组合分析师，并于2008年至2009年在芝加哥的普华永道担任审计助理。Wichterman先生是注册会计师（非在职），拥有威斯康星大学麦迪逊分校工商管理学士学位和会计学硕士学位。
- Troy Wichterman,has been Chief Financial Officer since November 2021. Before his appointment as Chief Financial Officer, Mr. Wichterman served as the Company's Vice President, Finance since November 2019. In that role, Mr. Wichterman oversaw the finance and accounting organization in the areas of integrating acquired businesses, acquisition due diligence and deal structure, SEC reporting, financial planning and analysis, operational finance, and audit compliance. Mr. Wichterman also served as Director of Financial Planning and Analysis from June 2016 to November 2019 and Financial Analyst from February 2015 to June 2016. Prior to joining the Company, he was most recently a Senior Financial Analyst, Acquisitions at Ventas, a public healthcare REIT, from January 2013 to September 2014. Prior to Ventas, he was most recently a Senior Portfolio Analyst at Heitman, a private equity REIT, from June 2009 – January 2013 and began his career as an Auditing Associate at PwC in Chicago from 2008 to 2009. Mr. Wichterman is a CPA (inactive) and holds a Bachelor of Business Administration degree and a Master of Accountancy degree from the University of Wisconsin – Madison.
- Sarah Aebersold
Sarah Aebersold，自2021年1月起担任全球人力资源副总裁。在被任命为全球人力资源副总裁之前，Aebersold女士自2020年2月起担任全球人力资源与行政高级总监。在这个职位上，埃伯索尔德负责管理员工关系、人才获取、福利、薪酬、辅导、培训和发展、政策和数据管理等领域的人力资源项目。在加入本公司之前，Aebersold女士曾在多家公司担任人力资源职务，包括医疗保健解决方案提供商MCG健康（2016-2020年，最近担任人力资源和行政主管）、医疗设备制造商Spacelabs Healthcare（2014-2016年、2012-2013年，最近担任人力资源高级经理）、移动通信公司T-Mobile（2013-2013年，最近担任人力资源经理）、儿童医院西雅图儿童医院（2009-2012年，最近担任人力资源咨询经理）和生物技术/制药公司ZymoGenetics，Inc.（2004-2009年，最近担任人力资源经理）。
Sarah Aebersold,has been Chief Human Resources Officer since January 2023. Previously, Ms. Aebersold was Vice President, Global Human Resources since January 2021 and served as the Senior Director, Global Human Resources & Administration since February 2020. In that role, Ms. Aebersold oversaw human resources programs in the areas of employee relations, talent acquisition, benefits, compensation, coaching, training and development, policy, and data management. Prior to joining the Company, Ms. Aebersold served in a variety of human resources roles with companies including MCG Health, a healthcare solutions provider (2016-2020, most recently as Head of Human Resources and Administration), Spacelabs Healthcare, a manufacturer of medical equipment (2014-2016, 2012-2013, most recently as Senior Manager, Human Resources), T-Mobile, a mobile communication company, (2013-2013, most recently as Human Resource Manager), Seattle Children's Hospital, a children's hospital (2009-2012, most recently as Manager, Human Resources Consulting), and ZymoGenetics, Inc., a biotechnology/pharmaceutical company (2004-2009, most recently as Human Resources Manager).- Sarah Aebersold，自2021年1月起担任全球人力资源副总裁。在被任命为全球人力资源副总裁之前，Aebersold女士自2020年2月起担任全球人力资源与行政高级总监。在这个职位上，埃伯索尔德负责管理员工关系、人才获取、福利、薪酬、辅导、培训和发展、政策和数据管理等领域的人力资源项目。在加入本公司之前，Aebersold女士曾在多家公司担任人力资源职务，包括医疗保健解决方案提供商MCG健康（2016-2020年，最近担任人力资源和行政主管）、医疗设备制造商Spacelabs Healthcare（2014-2016年、2012-2013年，最近担任人力资源高级经理）、移动通信公司T-Mobile（2013-2013年，最近担任人力资源经理）、儿童医院西雅图儿童医院（2009-2012年，最近担任人力资源咨询经理）和生物技术/制药公司ZymoGenetics，Inc.（2004-2009年，最近担任人力资源经理）。
- Sarah Aebersold,has been Chief Human Resources Officer since January 2023. Previously, Ms. Aebersold was Vice President, Global Human Resources since January 2021 and served as the Senior Director, Global Human Resources & Administration since February 2020. In that role, Ms. Aebersold oversaw human resources programs in the areas of employee relations, talent acquisition, benefits, compensation, coaching, training and development, policy, and data management. Prior to joining the Company, Ms. Aebersold served in a variety of human resources roles with companies including MCG Health, a healthcare solutions provider (2016-2020, most recently as Head of Human Resources and Administration), Spacelabs Healthcare, a manufacturer of medical equipment (2014-2016, 2012-2013, most recently as Senior Manager, Human Resources), T-Mobile, a mobile communication company, (2013-2013, most recently as Human Resource Manager), Seattle Children's Hospital, a children's hospital (2009-2012, most recently as Manager, Human Resources Consulting), and ZymoGenetics, Inc., a biotechnology/pharmaceutical company (2004-2009, most recently as Human Resources Manager).
- Sean Werner
肖恩·沃纳，自2024年11月起担任首席技术官。在被任命为首席技术官之前，Werner先生曾在2021年9月至2024年11月期间担任生命科学高级技术官。从2019年10月到2021年9月，Werner先生担任Sexton Biotechnologies，Inc的总裁，直到该公司被该公司收购。Werner先生还在2015年1月至2021年9月期间担任Cook Medical，Inc.（“Cook Medical”）的子公司Cook Regentec LLC的监管事务总监。2013年10月至2019年10月，他还在库克医疗担任细胞疗法监管科学总监一职。Werner先生在支持医疗设备、自体细胞治疗和单一Biolife Solutions，Inc. e一次性开发项目的科学、全球监管和一般管理职能方面拥有23年的综合经验。他指导了再生医学研究计划、临床前和临床测试以及导致医疗设备和生物加工工具全球商业化的提交策略。Werner先生拥有印第安纳大学生物学学士学位、普渡大学生物学博士学位，并曾在印第安纳大学医学院和礼来公司担任博士后职务。
Sean Werner,has been Chief Technology Officer since November 2024. Prior to his appointment as Chief Technology Officer, Mr. Werner served as Senior Technology Officer, Life Sciences from September 2021 through November 2024. From October 2019 through September 2021, Mr. Werner was President of Sexton Biotechnologies, Inc, until its acquisition by the Company. Mr. Werner additionally served as Director of Regulatory Affairs of Cook Regentec LLC, a subsidiary of Cook Medical, Inc. ("Cook Medical"), from January 2015 through September of 2021. He also held the position of Director of Regulatory Science, Cell Therapies while at Cook Medical from October 2013 through October 2019. Mr. Werner has a combined 23 years of experience in various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single Biolife Solutions, Inc. e disposable development programs. He has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools. Mr. Werner holds a BS in Biology from Indiana University, a PhD in Biology from Purdue University, and held post-doctoral positions at the Indiana University School of Medicine and Eli Lilly and Company.- 肖恩·沃纳，自2024年11月起担任首席技术官。在被任命为首席技术官之前，Werner先生曾在2021年9月至2024年11月期间担任生命科学高级技术官。从2019年10月到2021年9月，Werner先生担任Sexton Biotechnologies，Inc的总裁，直到该公司被该公司收购。Werner先生还在2015年1月至2021年9月期间担任Cook Medical，Inc.（“Cook Medical”）的子公司Cook Regentec LLC的监管事务总监。2013年10月至2019年10月，他还在库克医疗担任细胞疗法监管科学总监一职。Werner先生在支持医疗设备、自体细胞治疗和单一Biolife Solutions，Inc. e一次性开发项目的科学、全球监管和一般管理职能方面拥有23年的综合经验。他指导了再生医学研究计划、临床前和临床测试以及导致医疗设备和生物加工工具全球商业化的提交策略。Werner先生拥有印第安纳大学生物学学士学位、普渡大学生物学博士学位，并曾在印第安纳大学医学院和礼来公司担任博士后职务。
- Sean Werner,has been Chief Technology Officer since November 2024. Prior to his appointment as Chief Technology Officer, Mr. Werner served as Senior Technology Officer, Life Sciences from September 2021 through November 2024. From October 2019 through September 2021, Mr. Werner was President of Sexton Biotechnologies, Inc, until its acquisition by the Company. Mr. Werner additionally served as Director of Regulatory Affairs of Cook Regentec LLC, a subsidiary of Cook Medical, Inc. ("Cook Medical"), from January 2015 through September of 2021. He also held the position of Director of Regulatory Science, Cell Therapies while at Cook Medical from October 2013 through October 2019. Mr. Werner has a combined 23 years of experience in various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single Biolife Solutions, Inc. e disposable development programs. He has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools. Mr. Werner holds a BS in Biology from Indiana University, a PhD in Biology from Purdue University, and held post-doctoral positions at the Indiana University School of Medicine and Eli Lilly and Company.
- Roderick de Greef
Roderick de Greef，自2021年11月起担任BioLife的总裁兼首席运营官，直到他于2023年1月3日退休，并被任命为董事会董事。此前，de Greef先生于2016年5月至2021年11月被任命为首席财务官，并于2019年12月至2021年5月被任命为首席运营官。他于2016年3月被任命为临时首席财务官和临时秘书。他从2000年6月到2013年11月担任公司董事，并从2007年7月到2011年8月为公司提供战略和财务咨询服务。自2022年11月起，他担任Upper Connecticut Valley Hospital（New Hampshire北部的一家非营利性农村医院）的董事。自2020年12月以来，他一直担任Sirona Medical Technologies（一家心脏电生理公司）的董事。从2019年2月至2021年1月，de Greef先生担任印度尼西亚能源有限公司（一家石油和天然气勘探和生产公司）董事会审计委员会主席。他曾任职于Pareteum Corporation。从2015年9月到2017年9月，以及从2008年1月到2011年10月，担任董事、审计委员会主席、提名和公司治理委员会和薪酬委员会成员。从2013年11月到2014年10月，他担任Cambridge Cardiac Technologies, Inc. （Cambridge Heart, Inc.的私人继承者）的总裁和唯一董事。2008年11月至2013年10月，他担任Cambridge Heart, Inc.（非侵入性诊断心脏病学产品的制造商）的董事会主席。2003年11月至2013年5月，他担任Endologix, Inc.的董事、审计委员会成员和薪酬委员会主席。2001年至2006年，他担任纳斯达克上市公司Cardiac Science, Inc.的执行副总裁兼首席财务官，该公司在2004年被Deloitte & Touche的快速500强上市公司评为北美增长最快的科技公司第四名。他持有Oregon大学的工商管理硕士学位，以及San Francisco State大学的经济学和国际关系学士学位。
Roderick de Greef,has been Chief Executive Officer and Chairman of the Board since October 2023 at BioLife. Previously, Mr. de Greef began serving as a director of the Board in January 2023, prior to which he served as President and Chief Operating Officer from November 2021 until he retired on January 3, 2023. Mr. de Greef was appointed Chief Operating Officer from December 2019 to May 2021 after his appointment as Chief Financial Officer from May 2016 to November 2021. He also served as interim Chief Financial Officer and interim Secretary from March 2016 through May 2016. Mr. de Greef served as a director of the Company from June 2000 through November 2013 and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since November 2022, Mr. de Greef has served as a director of the Upper Connecticut Valley Hospital, a non-profit, rural hospital in northern New Hampshire. Since December 2020, Mr. de Greef has served as a director of Sirona Medical Technologies, a cardia electrophysiology company. From February 2019 to January 2021, Mr. de Greef served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation, a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of Cardiac Science, Inc. (which went private in September 2005), which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. Mr. de Greef received his Master of Business Administration degree from the University of Oregon, and a Bachelor of Arts in Economics and International Relations from San Francisco State University.- Roderick de Greef，自2021年11月起担任BioLife的总裁兼首席运营官，直到他于2023年1月3日退休，并被任命为董事会董事。此前，de Greef先生于2016年5月至2021年11月被任命为首席财务官，并于2019年12月至2021年5月被任命为首席运营官。他于2016年3月被任命为临时首席财务官和临时秘书。他从2000年6月到2013年11月担任公司董事，并从2007年7月到2011年8月为公司提供战略和财务咨询服务。自2022年11月起，他担任Upper Connecticut Valley Hospital（New Hampshire北部的一家非营利性农村医院）的董事。自2020年12月以来，他一直担任Sirona Medical Technologies（一家心脏电生理公司）的董事。从2019年2月至2021年1月，de Greef先生担任印度尼西亚能源有限公司（一家石油和天然气勘探和生产公司）董事会审计委员会主席。他曾任职于Pareteum Corporation。从2015年9月到2017年9月，以及从2008年1月到2011年10月，担任董事、审计委员会主席、提名和公司治理委员会和薪酬委员会成员。从2013年11月到2014年10月，他担任Cambridge Cardiac Technologies, Inc. （Cambridge Heart, Inc.的私人继承者）的总裁和唯一董事。2008年11月至2013年10月，他担任Cambridge Heart, Inc.（非侵入性诊断心脏病学产品的制造商）的董事会主席。2003年11月至2013年5月，他担任Endologix, Inc.的董事、审计委员会成员和薪酬委员会主席。2001年至2006年，他担任纳斯达克上市公司Cardiac Science, Inc.的执行副总裁兼首席财务官，该公司在2004年被Deloitte & Touche的快速500强上市公司评为北美增长最快的科技公司第四名。他持有Oregon大学的工商管理硕士学位，以及San Francisco State大学的经济学和国际关系学士学位。
- Roderick de Greef,has been Chief Executive Officer and Chairman of the Board since October 2023 at BioLife. Previously, Mr. de Greef began serving as a director of the Board in January 2023, prior to which he served as President and Chief Operating Officer from November 2021 until he retired on January 3, 2023. Mr. de Greef was appointed Chief Operating Officer from December 2019 to May 2021 after his appointment as Chief Financial Officer from May 2016 to November 2021. He also served as interim Chief Financial Officer and interim Secretary from March 2016 through May 2016. Mr. de Greef served as a director of the Company from June 2000 through November 2013 and provided the Company with strategic and financial consulting services from July 2007 through August 2011. Since November 2022, Mr. de Greef has served as a director of the Upper Connecticut Valley Hospital, a non-profit, rural hospital in northern New Hampshire. Since December 2020, Mr. de Greef has served as a director of Sirona Medical Technologies, a cardia electrophysiology company. From February 2019 to January 2021, Mr. de Greef served as a director, chairman of the Audit Committee of the board of directors of Indonesia Energy Corporation Limited, an oil and gas exploration and production company. Mr. de Greef served Pareteum Corporation, a mobile communications company, as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee from September 2015 to September 2017, and also from January 2008 to October 2011. From November 2013 to October 2014, Mr. de Greef served as the president and sole director of Cambridge Cardiac Technologies, Inc. a privately held successor to Cambridge Heart, Inc. From November 2008 to October 2013, Mr. de Greef was the chairman of the board of Cambridge Heart, Inc., a manufacturer of non-invasive diagnostic cardiology products. From November 2003 to May 2013, Mr. de Greef served as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc. From 2001 to 2006, Mr. de Greef served as Executive Vice President and Chief Financial Officer of Cardiac Science, Inc. (which went private in September 2005), which in 2004 was ranked as the 4th fastest growing technology company in North America on Deloitte & Touche's Fast 500 listing. Mr. de Greef received his Master of Business Administration degree from the University of Oregon, and a Bachelor of Arts in Economics and International Relations from San Francisco State University.
- Aby J. Mathew
Aby J. Mathew，自2019年12月起担任执行副总裁兼首席科学官。在被任命为执行副总裁兼首席科学官之前，他曾担任首席技术官。他是BioLife Solutions, Inc.的创始团队成员，自2000年以来一直受雇于BioLife。他是BioLife的生物保存介质解决方案的共同开发者，也是与保存细胞、组织和器官的方法、设备和配方相关的已发布和未决专利的共同发明人。他持有Binghamton University的生物科学博士学位和Cornell University的微生物学学士学位。自1994年以来，Mathew博士一直在研究低温生物保存，他的研究为BioLife当前商业HypoThermosol和CryoStor产品平台和知识产权基础的发展做出了贡献。Mathew博士目前活跃于AABB（前美国血库协会）、BEST（安全输血卓越生物医学合作组织）、国际细胞和基因治疗学会（ISCT）、再生医学联盟（ARM）、组织工程和再生医学国际学会（TERMIS）、低温生物学学会、国际生物和环境储存库学会（ISBER）、美国细胞生物学学会和体外生物学学会。Mathew博士是脐带血基金会家长指南、HemaCare公司科学顾问委员会、脐带血协会创始董事会成员、PanTHERA CryoSolutions公司董事会成员、NIST-AMTech国家细胞制造联盟成员、加州再生医学研究所（CIRM）临床顾问小组成员、RoosterBio公司商业顾问委员会成员。和SAVSU科技科学顾问委员会。他获得了加州大学洛杉矶分校公司治理项目认证。
Aby J. Mathew,has been Executive Vice President and Chief Scientific Officer since December 2019. Before his appointment as Executive Vice President and Chief Scientific Officer, Dr. Mathew had served as Chief Technology Officer. Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and has been employed by BioLife since 2000. Dr. Mathew is a co-developer of BioLife's biopreservation media solutions and co-inventor on issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife's current commercial HypoThermosol and CryoStor product platforms and intellectual property foundation. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of the Board of Directors and Advisory Panel, a board member of the Parent's Guide to Cord Blood Foundation, a founding member of the Board of Directors of the Cord Blood Association, a member of the Business Advisory Board of RoosterBio Inc., and was a member of the Board of Directors of PanTHERA CryoSolutions, Inc. from November 2020 to April 2025. Dr. Mathew has obtained the UCLA Corporate Governance Program Certification.- Aby J. Mathew，自2019年12月起担任执行副总裁兼首席科学官。在被任命为执行副总裁兼首席科学官之前，他曾担任首席技术官。他是BioLife Solutions, Inc.的创始团队成员，自2000年以来一直受雇于BioLife。他是BioLife的生物保存介质解决方案的共同开发者，也是与保存细胞、组织和器官的方法、设备和配方相关的已发布和未决专利的共同发明人。他持有Binghamton University的生物科学博士学位和Cornell University的微生物学学士学位。自1994年以来，Mathew博士一直在研究低温生物保存，他的研究为BioLife当前商业HypoThermosol和CryoStor产品平台和知识产权基础的发展做出了贡献。Mathew博士目前活跃于AABB（前美国血库协会）、BEST（安全输血卓越生物医学合作组织）、国际细胞和基因治疗学会（ISCT）、再生医学联盟（ARM）、组织工程和再生医学国际学会（TERMIS）、低温生物学学会、国际生物和环境储存库学会（ISBER）、美国细胞生物学学会和体外生物学学会。Mathew博士是脐带血基金会家长指南、HemaCare公司科学顾问委员会、脐带血协会创始董事会成员、PanTHERA CryoSolutions公司董事会成员、NIST-AMTech国家细胞制造联盟成员、加州再生医学研究所（CIRM）临床顾问小组成员、RoosterBio公司商业顾问委员会成员。和SAVSU科技科学顾问委员会。他获得了加州大学洛杉矶分校公司治理项目认证。
- Aby J. Mathew,has been Executive Vice President and Chief Scientific Officer since December 2019. Before his appointment as Executive Vice President and Chief Scientific Officer, Dr. Mathew had served as Chief Technology Officer. Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and has been employed by BioLife since 2000. Dr. Mathew is a co-developer of BioLife's biopreservation media solutions and co-inventor on issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife's current commercial HypoThermosol and CryoStor product platforms and intellectual property foundation. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of the Board of Directors and Advisory Panel, a board member of the Parent's Guide to Cord Blood Foundation, a founding member of the Board of Directors of the Cord Blood Association, a member of the Business Advisory Board of RoosterBio Inc., and was a member of the Board of Directors of PanTHERA CryoSolutions, Inc. from November 2020 to April 2025. Dr. Mathew has obtained the UCLA Corporate Governance Program Certification.